Breaking Finance News

Bio-Rad Laboratories, Inc. (NYSE:BIO) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has downgraded Bio-Rad Laboratories, Inc. (NYSE:BIO) to Hold in a statement released on 7/05/2017.

On 06/28/2017, Deutsche Bank released a statement on Bio-Rad Laboratories, Inc. (NYSE:BIO) upped the target price from $220.00 to $255.00 that suggested an upside of 0.17%.

Having a price of $231.69, Bio-Rad Laboratories, Inc. (NYSE:BIO) traded -1.33% lower on the day. With the last close up 0.42% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. BIO has recorded a 50-day average of $228.90 and a two hundred day average of $213.25. Trade Volume was down over the average, with 88,247 shares of BIO changing hands under the typical 149,928

Recent Performance Chart

Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. has PE ratio of 423.20 with a one year low of $147.68 and a one year high of $242.79 and has a market capitalization of $0.

A total of 2 analysts have released a report on Bio-Rad Laboratories, Inc.. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $176.00.

General Company Details For Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.